battle of glp-1 delivery technologies New Drug System Could Reduce Shortage and Make It More Efficient Designing GLP-1 delivery: structural perspectives

This feedback mechanism was valuable for our hunter-gatherer ancestors, but it doesn't work so well for modern humans who have easy access to energy dense ultra-processed foods

And theyll dispense it at a pharmacy where the pharmacist will never check on the patient after handing the glp1 over - Not because the pharmacist doesnt care but because their business model (CVS) literally prevents care

Hagstrm, H

However, since mitochondria are heavily damaged during this aging model and neither in vivo experiments with Nox3-deficient animals nor in vitro experiments with Nox3 knock-down in cells were conducted, the explicit role and the contribution of Nox3-derived ROS in comparison to ROS produced by the damaged mitochondria remained elusive